Search
News
Applied Materials Inc Stock Moved Up by 3.97% on Feb 25: A Full Analysis
• Applied Materials beat Q1 2026 earnings and revenue expectations. • Company projects strong Q2 2026 revenue and EPS, exceeding estimates. • AI demand and new technologies position Applied Materials for growth.
TradingKey
Wed, Feb 25
Optical Communication Stocks Jump. Lumentum Soars Nearly 10%; Coherent up 8%; Lumen Technologies up over 7%; Fabrinet up 6%
Optical communication stocks jumped. Lumentum rose nearly 10%; Coherent rose over 8%; Lumen Technologies rose over 7%; Fabrinet rose nearly 6%; Corning up over 3%.Tiger News
Wed, Feb 25
Lam Research Corp Stock Opened Up by 3.04% on Feb 25: Drivers Behind the Movement
• Lam Research surpassed Q2 FY2026 expectations with strong guidance. • AI and advanced technologies drive demand for Lam Research's equipment. • Semiconductor market growth supports Lam Research's positive outlook.
TradingKey
Wed, Feb 25
South Korea-Focused ETFs Climb as Korea Composite Index Surges to Tops 6,000. Direxion Daily South Korea Bull ETF Soars 6%
ETFs listed in the United States that track South Korean equities, such as the iShares MSCI Korea ETF and the Franklin FTSE Korea ETF, have posted significant gains. The rise follows advances in the Korea Composite Stock Price Index, driven by strength in technology stocks and robust inflows of fore...Tiger News
Wed, Feb 25
Crypto Shares Jump Premarket. BitMine, Strategy up Around 3%; SoFi, Circle, CleanSpark, Coinbase, MARA, SBET up Around 2%
Crypto shares jumped in premarket trading. BitMine, Strategy up around 3%; SoFi, Circle, CleanSpark, Coinbase, MARA Holdings, SBET up around 2%.Bitcoin pushed back above $65,000 on Wednesday, tracking a broader rebound in risk assets after several sessions of turbulence.Tiger News
Wed, Feb 25
Premarket Movers | Axon Enterprise Surges 16%; Tempus AI, MercadoLibre Slide 4% Each; HP Drops 5%; Workday Falls 9%; First Solar Sinks 14%
Taser-maker Axon Enterprise beat Wall Street estimates for fourth-quarter profit, driven by strong demand for its security devices and software products. Shares of the Arizona-based company were up 15.7% in premarket trading.MercadoLibre posted a 12.5% decline in quarterly profit, missing analysts' ...Tiger News
Wed, Feb 25
Top 10 HK Stock Gainers (2.25)
XIMEI RESOURCES(09936) rose 23.44%, with a trading turnover 30.9 Million HKD, and a year-to-date rose 118.8%. MOKINGRAN(02585) rose 21.51%, with a trading turnover 130.0 Million HKD, and a year-to-date rose 31%. AGTECH HOLDINGS(08279) rose 19.74%, with a trading turnover 50.5 Million HKD, and a year-to-date rose 126.4%.Longport
Wed, Feb 25
Top 10 HK Stock Losers (2.25)
MINIMAX-WP(00100) fell 14.38%, with a trading turnover 2.3 Billion HKD, and a year-to-date rose 356.7%. HAIZHI TECH GP(02706) fell 11.63%, with a trading turnover 512.2 Million HKD, and a year-to-date rose 298.7%. KNOWLEDGE ATLAS(02513) fell 10.75%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 382.4%.Longport
Wed, Feb 25
Top 5 HK Stock Gainers/Losers (>100B) (2.25)
BEKE-W(02423) rose 5.63%, with a trading turnover 826.8 Million HKD, and a year-to-date rose 12%. CONCH CEMENT(00914) rose 5.53%, with a trading turnover 764.8 Million HKD, and a year-to-date rose 20.9%. MINIMAX-WP(00100) fell 14.38%, with a trading turnover 2.3 Billion HKD, and a year-to-date rose 356.7%. KNOWLEDGE ATLAS(02513) fell 10.75%, with a trading turnover 1.7 Billion HKD, and a year-to-date rose 382.4%.Longport
Wed, Feb 25
6 Takeaways from Trump's State of the Union Speech
Trump delivered his State of the Union address in Congress on Tuesday.Key takeaways include his comments on tariffs, lower consumer prices, and AI driving up energy costs.It was the longest speech in the country's recent history.President Donald Trump gave his annual State of the Union address on Tu...Tiger News
Wed, Feb 25
Proposed US$ 100 million credit facility from KfW IPEX-Bank
EQS Newswire / 25/02/2026 / 09:36 MSKSolidcore Resources plc (“Solidcore” or the “Company”) is pleased to announce that the Company has signed an indicative term sheet with KfW IPEX-Bank for a seven-year credit facility of up to US$ 100 million to finance construction of the Ertis POX project including infrastructure, equipment and engineering costs.“Our partnership with KfW IPEX-Bank to finance Ertis POX construction marks an important milestone for Solidcore. This term sheet is the first arrangement within the broader funding framework for the project which reflects the strong confidence of our international financial partners in our strategy and long-term vision. We continue working with other banks to secure a total of US$ 600 mln of financing for Ertis POX this year”, said Evgenia Onuschenko, CFO of Solidcore Resources plc. “We are delighted to have been invited to contribute to the financing of this important project and thus to be able to supporting European exports.”, said Wolfgang Behler, Global Head of Industries and Commerce at KfW IPEX-Bank.About Ertis POXErtis POX is Kazakhstan’s first large-scale and high-tech full-cycle pressure oxidation plant for refractory ore processing in the country. Capital expenditures for the project are estimated at US$ 978 million and will be funded through a combination of the Company’s operating cash flow and bank financing. New POX facility will process up to 300,000 tons of gold-bearing concentrate and produce up to 500 Koz of gold in dore alloy per year. It is intended to create approximately 500 permanent new jobs in the region and 1,000 jobs during the construction period.About KfW IPEX-BankKfW IPEX-Bank is a leading German and international project and export finance bank, founded in 2008 as a wholly owned subsidiary of the state-owned KfW Group. With a strong European foundation and a global presence, it supports European and global companies in key sectors including infrastructure, energy, transport, and industrial projects. The bank provides tailored financing solutions, backed by deep sector expertise and a clear focus on sustainability and responsible financing.About SolidcoreSolidcore Resources is a leading gold producer registered in AIFC, Kazakhstan, and listed on Astana International Exchange. Solidcore operates two producing gold mines and a major growth project (Ertis POX) in Kazakhstan.Enquiries Investor Relations Media Kirill Kuznetsov Alina Assanova +7 7172 47 66 55 (Kazakhstan) ir@solidcore-resources.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@solidcore-resources.kz FORWARD-LOOKING STATEMENTSThis release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.25/02/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Wed, Feb 25
CRCL: Results Push Back at Bears — Can the First Stablecoin Stock Stay Steady? ---
Pre-market on Feb 25 ET, the USDC stablecoin issuer $Circle(CRCL.US) reported Q4 2025 results.While reserve interest income, its largest revenue component, is fairly transparent given public USDC market cap and Fed rates, and Circle’s share price is not tightly linked to quarterly prints, we can sti...Dolphin Research
Wed, Feb 25
Crypto Daily｜Bitcoin Retakes $65,000; Trump Won’T Pardon FTX’S SBF; Meta Reportedly Eyes Stablecoin Integration This Year
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsBitcoin retakes $65,000Bitcoin pushed back above $65,000 on Wednesday, tracking a broader rebound in risk assets after several sessions of turbulence.Trump Won’t Pa...Tiger News
Wed, Feb 25
CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD
Suzhou, China, February 24, 2026 — CF PharmTech, Inc. (HKEX: 2652.HK) (“CF PharmTech” or the “Company”) today announced that the Investigational New Drug (“IND”) application for ICF004, the Company’s internally developed first-in-class (FIC) inhaled dry powder candidate for the treatment of pulmonary fibrosis (a Class 1 chemical drug candidate), has been accepted by the National Medical Products Administration of China (“NMPA”).The acceptance of the ICF004 IND application marks a key step forward in the Company’s innovative drug research and development efforts and an important milestone in advancing translational innovation based on the Company’s complex respiratory formulation and precision delivery platform. The Company believes progress in the ICF004 program not only supports the clinical development value of a standalone pipeline asset, but also demonstrates its ability to translate high-barrier delivery and formulation platform capabilities into innovative drug clinical development assets.Addressing Unmet Needs in PF-ILD: Resolving Efficacy-Tolerability DilemmaICF004 is intended for the treatment of Progressive Fibrosing Interstitial Lung Disease (“PF-ILD”), a disease area that includes life-threatening indications such as Idiopathic Pulmonary Fibrosis (“IPF”) and Progressive Pulmonary Fibrosis (“PPF”).PF-ILD is characterized by progressively worsening respiratory symptoms and irreversible decline in lung function, and is generally associated with poor prognosis. Using IPF as a representative condition, publicly available data indicate a median survival of approximately 2.8 years and a 5-year survival rate below 40%, underscoring the substantial clinical burden of disease.Oral therapies have been approved globally for the treatment of IPF. Public clinical data and real-world evidence suggest that, while existing therapies may slow decline in lung function to some extent, some patients still face limited survival benefit, significant adverse-event burden, and treatment interruption or discontinuation. For patients coping with both disease progression and treatment-related side effects, there remains an urgent global need for next-generation therapies that can better balance safety, efficacy, and long-term treatment adherence.The Company believes the development rationale for ICF004 is grounded in these unmet needs. The program seeks to explore new delivery and therapeutic pathways on top of existing treatment approaches, with the goal of improving the therapeutic window and patient outcomes.Improving Therapeutic Window Through the Integration of Mechanism Exploration and Formulation Innovation Through Local Targeted DeliveryBased on the Company’s current development strategy, ICF004 uses an inhaled dry powder delivery route designed to deliver the drug directly to lung lesion areas, thereby increasing local pulmonary exposure while minimizing systemic exposure to the extent possible, in pursuit of a better balance between efficacy and safety.The Company positions ICF004 as a candidate integrating mechanism exploration and formulation innovation, and continues to conduct mechanistic research and translational validation around fibrosis-related pathological processes, including inflammation, oxidative stress, and fibroblast activation.Preclinical Findings Demonstrate Differentiated Pulmonary Exposure Profile Supporting Development StrategyAccording to the Company’s completed preclinical studies, ICF004 demonstrated differentiated distribution characteristics between lung tissue exposure and systemic blood exposure following inhaled administration. In relevant studies, the Company observed a significant exposure differential between lung and blood, supporting the project’s subsequent development strategy centered on improving target-organ exposure efficiency and reducing systemic exposure burden through local targeted delivery.In addition, the Company observed anti-fibrotic activity trends for ICF004 in relevant preclinical models. These findings provide supportive information for subsequent clinical development; however, whether they will translate into clinical efficacy and safety advantages in humans remains to be verified in future clinical trials.Platform Validation: Extending from Complex Formulation to Innovative Drug Translational Capability and Strategic SignificanceThe acceptance of the ICF004 IND application marks the first time one of the Company’s innovative drug programs has entered the regulatory acceptance stage. The Company believes the strategic significance of this progress is reflected primarily in the following areas:Validation of platform translational capability — demonstrating the Company’s ability to integrate complex formulations, delivery systems, device engineering, and unmet clinical needs in advancing innovative drug development programs; Strengthening the replicability of R&D pathways — providing methodological and organizational experience for subsequent innovative programs in respiratory and related therapeutic areas; and Enhancing capital market understanding of the Company’s platform-based capabilities — helping investors better understand, beyond the complex formulation business alone, the Company’s medium- to long-term capabilities and potential value drivers in combining delivery technologies, device engineering, and innovative drug clinical translation.Leveraging its capabilities in inhalation delivery, device engineering, regulatory registration, and industrialization, CF PharmTech continues to advance a multi-layered product portfolio and explore opportunities in delivery-enabled innovative drug development across broader disease areas.Next StepsThe Company will continue to advance subsequent clinical development activities for ICF004 in accordance with NMPA requirements, including clinical start-up preparation, subject enrollment arrangements, and phased data readouts.At the same time, the Company will prudently evaluate strategic pathways such as independent development and collaborative development based on the project’s clinical progress, resource allocation, and external partnership opportunities, and will fulfill information disclosure obligations in a timely manner in accordance with applicable regulatory requirements.Important Risks and DisclaimersInnovative drug R&D involves high investment, long development timelines, and significant risks. Uncertainties remain in the subsequent clinical development, regulatory review and approval, and commercialization process of ICF004. The Company reminds investors to exercise rational judgment and be mindful of the risks associated with investing.About CF PharmTechCF PharmTech focuses on the development of complex formulations, small nucleic acid and liposomal drugs, and precision delivery technologies in key therapeutic areas such as respiratory diseases, and has capabilities in inhalation delivery, device engineering, regulatory registration, and industrialization. The Company is advancing a multi-layered product portfolio based on these platform capabilities and continues to explore clinical translation opportunities in innovative drug development.Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements, including but not limited to statements relating to the development, clinical progress, regulatory review, and potential commercialization of ICF004, and the Company’s strategic plans and expectations. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to, risks related to clinical development, regulatory approval, commercialization, market conditions, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law or regulation.25/02/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Wed, Feb 25
HK Mainland Real Estate Shares Rally. CH OVS G Oceans And Country Gardenup 8%; LVGEM China, China Res Land, Longfor, Agile, Greentown And Cifi Up 5%
HK Mainland Real Estate Shares Rally. CH OVS G Oceans and Country Gardenup 8%; LVGEM China, China Res Land, Longfor, Agile, Greentown and Cifi up 5%.Tiger News
Wed, Feb 25
Featured Tools
Top News
KOSPI and Nikkei 225 Both Tumble 2%, Kioxia Slumps 7% as SoftBank, Samsung and SK Hynix Plunge Across the Board
The Week Ahead: September FOMC Rate Decision and Dot Plot Ahead, Trip.com and Lennar Earnings in Focus
JPMorgan Stock Holds $348 Ahead of Fed Week as Bulls Eye $356
What Is XRP? How Will the Clarity Act Impact XRP's Regulatory Status and Future Value?
Qualcomm Stock Forecast: Can QCOM Hit $200 After Amazon AI Chip Partnership?
